Mechanism

An investigational dual GLP-1 and glucagon receptor agonist. In research the combined activity is hypothesized to address appetite and glycemia (GLP-1) alongside increased energy expenditure (glucagon).

Research summary

Investigational and not FDA-approved. It has been studied for weight management and type 2 diabetes, with trials reported particularly in China. Larger-scale evaluation continues per the literature.

Reported side effects

Gastrointestinal effects are the most commonly reported in trials, consistent with the incretin class. Given glucagon activity, metabolic parameters are monitored. The full safety profile is not yet established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Mazdutide (IBI362 / LY3305677) clinical trials · peer-reviewed clinical trials (2023)search PubMed for mazdutide; investigational
GLP-1/glucagon dual agonist reviews · peer-reviewed review articles (2023)investigational; not FDA-approved

Το TrackPep είναι εφαρμογή παρακολούθησης. Καταγράφει όσα καταχωρίζεις και ποτέ δεν προτείνει ούτε υπολογίζει ποσότητες.